Jung Ki Jo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jung Ki Jo has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
Sang Eun Lee
Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
8 shared publications- Seok-Soo Byun
Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
6 shared publications - Chang Wook Jeong
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
5 shared publications - Cheol Kwak
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
5 shared publications - Hongyun So
Hanyang University
5 shared publications - Jae Young Park
Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
5 shared publications
Latest Publications
- 10 November 2026
- Published by Wolters Kluwer Health in Hypertension
Extravascular Renal Denervation for Resistant Hypertension: First-in-Human Study
BACKGROUND: Catheter-based intravascular renal denervation produces modest, variable blood pressure reductions, partly because renal sympathetic nerves lie at variable depths within the periarterial adventitia and because accessory or early branching arteries are inaccessible to intraluminal catheters. We developed an extravascular renal denervation system (HyperQure) delivering circumferential radiofrequency energy from outside the artery and assessed its safety and efficacy. Here, we report the primary 3-month outcomes. METHODS: This prospective, multicenter, single-arm, first-in-human pilot trial enrolled 10 patients with resistant hypertension (office blood pressure ≥140/90 mm Hg and daytime ambulatory systolic blood pressure [SBP] ≥135 mm Hg despite ≥3 antihypertensive agents) across 7 Korean centers. All underwent bilateral extravascular renal denervation on stable antihypertensive regimens. The primary end point was 3-month change in 24-hour ambulatory SBP; safety outcomes were assessed through 3 months. RESULTS: All 10 patients (median age, 52.5 years; 7 men) completed follow-up. Seven patients (70%) had accessory or early branching arteries P =0.008) and median office SBP by 39.5 mm Hg ( P =0.002). Seven of 10 (70%) achieved office SBP <140 mm Hg despite a reduction in median antihypertensive burden from 6.0 to 4.5 agents. No major or procedure-related adverse events occurred; follow-up computed tomography angiography showed no vascular complications and renal function was preserved. CONCLUSIONS: Extravascular renal denervation using the HyperQure renal denervation System warrants evaluation in a larger controlled trial, particularly in patients with complex renal arterial anatomy.
- 10 November 2026
- Published by Wolters Kluwer Health in Hypertension
Extravascular Renal Denervation for Resistant Hypertension: First-in-Human Study
BACKGROUND: Catheter-based intravascular renal denervation produces modest, variable blood pressure reductions, partly because renal sympathetic nerves lie at variable depths within the periarterial adventitia and because accessory or early branching arteries are inaccessible to intraluminal catheters. We developed an extravascular renal denervation system (HyperQure) delivering circumferential radiofrequency energy from outside the artery and assessed its safety and efficacy. Here, we report the primary 3-month outcomes. METHODS: This prospective, multicenter, single-arm, first-in-human pilot trial enrolled 10 patients with resistant hypertension (office blood pressure ≥140/90 mm Hg and daytime ambulatory systolic blood pressure [SBP] ≥135 mm Hg despite ≥3 antihypertensive agents) across 7 Korean centers. All underwent bilateral extravascular renal denervation on stable antihypertensive regimens. The primary end point was 3-month change in 24-hour ambulatory SBP; safety outcomes were assessed through 3 months. RESULTS: All 10 patients (median age, 52.5 years; 7 men) completed follow-up. Seven patients (70%) had accessory or early branching arteries P =0.008) and median office SBP by 39.5 mm Hg ( P =0.002). Seven of 10 (70%) achieved office SBP <140 mm Hg despite a reduction in median antihypertensive burden from 6.0 to 4.5 agents. No major or procedure-related adverse events occurred; follow-up computed tomography angiography showed no vascular complications and renal function was preserved. CONCLUSIONS: Extravascular renal denervation using the HyperQure renal denervation System warrants evaluation in a larger controlled trial, particularly in patients with complex renal arterial anatomy.
- Open Access
- 21 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6488
Reprogramming the Evolution of High-Risk Prostate Cancer: Multidisciplinary Strategies to Delay Castration Resistance
Background/Objectives: High-risk prostate cancer is a biologically heterogeneous group of tumors carrying a substantial risk of progression to lethal, castration-resistant disease. Although androgen deprivation therapy (ADT) remains the therapeutic backbone, nearly all advanced disease eventually progresses to castration-resistant prostate cancer (CRPC) through Darwinian clonal evolution under sustained therapeutic pressure. This narrative review reframes high-risk prostate cancer management as an effort to reprogram the evolutionary trajectory and delay castration resistance, addressing current risk stratification, androgen receptor (AR)-dependent and AR-independent mechanisms of resistance, and multidisciplinary strategies that modify selective pressure. Methods: A narrative review of the literature was conducted, including peer-reviewed studies, pivotal phase III trial reports, and current clinical practice guidelines indexed in PubMed, Scopus, and Web of Science up to 2026. Sources on high-risk and castration-resistant prostate cancer, the biology of treatment resistance, and multidisciplinary treatment intensification were selected and synthesized. Results: Treatment intensification has been extended to high-risk biochemical recurrence (EMBARK), directed by biomarkers in PTEN-deficient disease (CAPItello-281), and moved earlier through prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PSMAfore, PSMAddition). In localized disease, effective AR-pathway intensification with abiraterone (STAMPEDE) contrasts with the failure of chemotherapy (PEACE-2) and enzalutamide (ENZARAD). Emerging therapies targeting lineage plasticity exploit its dynamic and potentially reversible biology, raising the prospect of reversing established resistance rather than merely delaying it. CAPItello-281 and PSMAddition have immature overall survival data and are not yet standard of care. Conclusions: Coordinated multidisciplinary care, matched to the disease stage and molecular context, offers a realistic path to delay castration resistance and improve survival.
- 21 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6488
Open AccessReprogramming the Evolution of High-Risk Prostate Cancer: Multidisciplinary Strategies to Delay Castration Resistance
Background/Objectives: High-risk prostate cancer is a biologically heterogeneous group of tumors carrying a substantial risk of progression to lethal, castration-resistant disease. Although androgen deprivation therapy (ADT) remains the therapeutic backbone, nearly all advanced disease eventually progresses to castration-resistant prostate cancer (CRPC) through Darwinian clonal evolution under sustained therapeutic pressure. This narrative review reframes high-risk prostate cancer management as an effort to reprogram the evolutionary trajectory and delay castration resistance, addressing current risk stratification, androgen receptor (AR)-dependent and AR-independent mechanisms of resistance, and multidisciplinary strategies that modify selective pressure. Methods: A narrative review of the literature was conducted, including peer-reviewed studies, pivotal phase III trial reports, and current clinical practice guidelines indexed in PubMed, Scopus, and Web of Science up to 2026. Sources on high-risk and castration-resistant prostate cancer, the biology of treatment resistance, and multidisciplinary treatment intensification were selected and synthesized. Results: Treatment intensification has been extended to high-risk biochemical recurrence (EMBARK), directed by biomarkers in PTEN-deficient disease (CAPItello-281), and moved earlier through prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PSMAfore, PSMAddition). In localized disease, effective AR-pathway intensification with abiraterone (STAMPEDE) contrasts with the failure of chemotherapy (PEACE-2) and enzalutamide (ENZARAD). Emerging therapies targeting lineage plasticity exploit its dynamic and potentially reversible biology, raising the prospect of reversing established resistance rather than merely delaying it. CAPItello-281 and PSMAddition have immature overall survival data and are not yet standard of care. Conclusions: Coordinated multidisciplinary care, matched to the disease stage and molecular context, offers a realistic path to delay castration resistance and improve survival.
- Open Access
- 9 July 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 268
A lipid-tuned bile acid exporter: structural insight into intestinal bile acid efflux
- 9 July 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 268
Open AccessA lipid-tuned bile acid exporter: structural insight into intestinal bile acid efflux
- Open Access
- 2 April 2026
- Published by Elsevier in SSRN Electronic Journal
FeN4 sites in carbon-based graphitic materials as key active centers for electrochemical sensing
Iron-nitrogen coordination-embedded graphene materials with varying Fe contents (FeNC) were synthesized via controlled pyrolysis to investigate the structure-performance relationship between Fe single-atom sites and Fe nanoparticles in electrocatalysis. Comprehensive structural and electrochemical characterization revealed that graphene predominantly containing isolated FeN4 sites exhibited the most favorable electronic structure and superior catalytic performance. In contrast, higher Fe loadings led to the formation of aggregated Fe species within the carbon matrix, resulting in diminished catalytic activity. Density functional theory (DFT) calculations further demonstrated that FeN4 sites provided energetically favorable adsorption configurations and reaction pathways for hydrogen peroxide (H2O2). The optimized FeNC material (Fe0.5%) was subsequently evaluated for electrochemical sensing of H2O2, showing high sensitivity and selectivity even in the presence of eleven common interfering species found in human urine. For practical clinical validation, the sensor was tested using urine samples from six healthy individuals and six patients diagnosed with prostate cancer. Significantly elevated H2O2 levels were observed in the prostate cancer group, with statistically significant difference. These findings highlight the potential of FeNC as a versatile and tunable platform for electrochemical sensing and bioanalytical applications.
- 2 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFeN4 sites in carbon-based graphitic materials as key active centers for electrochemical sensing
Iron-nitrogen coordination-embedded graphene materials with varying Fe contents (FeNC) were synthesized via controlled pyrolysis to investigate the structure-performance relationship between Fe single-atom sites and Fe nanoparticles in electrocatalysis. Comprehensive structural and electrochemical characterization revealed that graphene predominantly containing isolated FeN4 sites exhibited the most favorable electronic structure and superior catalytic performance. In contrast, higher Fe loadings led to the formation of aggregated Fe species within the carbon matrix, resulting in diminished catalytic activity. Density functional theory (DFT) calculations further demonstrated that FeN4 sites provided energetically favorable adsorption configurations and reaction pathways for hydrogen peroxide (H2O2). The optimized FeNC material (Fe0.5%) was subsequently evaluated for electrochemical sensing of H2O2, showing high sensitivity and selectivity even in the presence of eleven common interfering species found in human urine. For practical clinical validation, the sensor was tested using urine samples from six healthy individuals and six patients diagnosed with prostate cancer. Significantly elevated H2O2 levels were observed in the prostate cancer group, with statistically significant difference. These findings highlight the potential of FeNC as a versatile and tunable platform for electrochemical sensing and bioanalytical applications.
- Open Access
- 22 February 2026
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 12 (2) , e70076
Cancer‐associated fibroblasts are associated with CD8 + T cell depletion and poor prognosis in colorectal adenocarcinoma: a multi‐omics and machine learning analysis
Fibroblastic proliferation in various tumor microenvironments influences cancer survival through complex interactions with diverse immune responses. This study investigated the impact of histologically unique activated cancer‐associated fibroblasts (aCAFs) on survival outcomes and immune responses and examined their association with various pathophysiological mechanisms. We analyzed a total of 1,024 colorectal adenocarcinoma patients from two cohorts. aCAFs were evaluated based on hematoxylin and eosin‐stained whole‐slide images, and their associations with clinicopathological features, immune cell infiltration, and survival were assessed. We developed a machine learning‐based survival prediction model incorporating aCAFs and clinicopathologic parameters. Additionally, we performed differential gene expression analysis, functional enrichment analyses, and in vitro drug screening of aCAF‐related genes. aCAFs were associated with advanced T stage, lymphovascular invasion, perineural invasion, and decreased CD8+ and CD4+ T cell infiltration. aCAFs were also associated with worse overall and disease‐free survival in both univariate and multivariate analyses. Functional enrichment analysis revealed that aCAF‐related genes were implicated in immunosuppressive signaling, oxidative stress regulation, and tumor progression pathways. Survival prediction models based on machine learning and incorporating aCAFs demonstrated superior prognostic accuracy for overall survival and disease‐free survival compared to models excluding aCAFs. Our analysis of aCAFs' association with immune responses through bioinformatics‐based genomic analysis and machine learning provides a foundation for future research in CRC patients.
- 22 February 2026
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 12 (2) , e70076
Open AccessCancer‐associated fibroblasts are associated with CD8 + T cell depletion and poor prognosis in colorectal adenocarcinoma: a multi‐omics and machine learning analysis
Fibroblastic proliferation in various tumor microenvironments influences cancer survival through complex interactions with diverse immune responses. This study investigated the impact of histologically unique activated cancer‐associated fibroblasts (aCAFs) on survival outcomes and immune responses and examined their association with various pathophysiological mechanisms. We analyzed a total of 1,024 colorectal adenocarcinoma patients from two cohorts. aCAFs were evaluated based on hematoxylin and eosin‐stained whole‐slide images, and their associations with clinicopathological features, immune cell infiltration, and survival were assessed. We developed a machine learning‐based survival prediction model incorporating aCAFs and clinicopathologic parameters. Additionally, we performed differential gene expression analysis, functional enrichment analyses, and in vitro drug screening of aCAF‐related genes. aCAFs were associated with advanced T stage, lymphovascular invasion, perineural invasion, and decreased CD8+ and CD4+ T cell infiltration. aCAFs were also associated with worse overall and disease‐free survival in both univariate and multivariate analyses. Functional enrichment analysis revealed that aCAF‐related genes were implicated in immunosuppressive signaling, oxidative stress regulation, and tumor progression pathways. Survival prediction models based on machine learning and incorporating aCAFs demonstrated superior prognostic accuracy for overall survival and disease‐free survival compared to models excluding aCAFs. Our analysis of aCAFs' association with immune responses through bioinformatics‐based genomic analysis and machine learning provides a foundation for future research in CRC patients.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Four Decades of Medical Research in the Journal of Korean Medical Science : A Bibliometric Network Analysis (1986–2025)
Kim H, et al. J Korean Med Sci. 2026 Dec;41:e305. https://doi.org/10.3346/jkms.2026.41.e305
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Open AccessFour Decades of Medical Research in the Journal of Korean Medical Science : A Bibliometric Network Analysis (1986–2025)
Kim H, et al. J Korean Med Sci. 2026 Dec;41:e305. https://doi.org/10.3346/jkms.2026.41.e305
- Open Access
- 1 January 2026
- Published by XMLink in Investigative and Clinical Urology
- Vol. 67 (5) , 459-467
Predictors of active surveillance discontinuation in prostate cancer: Large Korean multicenter cohort study
Choi J, et al. Investig Clin Urol. 2026 Sep;67(5):459-467. https://doi.org/10.4111/icu.20260118
- 1 January 2026
- Published by XMLink in Investigative and Clinical Urology
- Vol. 67 (5) , 459-467
Open AccessPredictors of active surveillance discontinuation in prostate cancer: Large Korean multicenter cohort study
Choi J, et al. Investig Clin Urol. 2026 Sep;67(5):459-467. https://doi.org/10.4111/icu.20260118
- Open Access
- 13 May 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e63030
Analyzing Usage of the Metaverse by Associations of Patients With Prostate Cancer During the 2023 Blue Ribbon Campaign: Cross-Sectional Survey Study
Background: It is important to explain early diagnosis and treatment plans to patients of prostate cancer due to the different stages that diagnosis is made at and the corresponding stage-specific treatment options, as well as the varying prognoses depending on the choices made. Although various studies have implemented metaverse-based interventions across diverse clinical settings for medical education, there is a lack of publications addressing the implementation and validation of patient education using this technology. Objective: This study explored the potential of the metaverse as an educational and informational tool for prostate cancer. We measured and analyzed participants’ satisfaction and perceptions following a metaverse-based prostate cancer awareness campaign. We also evaluated the feasibility and potential effectiveness of the metaverse as a platform for hosting a virtual patient association and delivering health education. Methods: The study was conducted via a questionnaire administered from September 15 to October 20, 2023, during the Blue Ribbon Campaign organized by the Korean Urological Association and the Korean Society of Urological Oncology. The postevent questionnaire was designed to assess the effectiveness of using the metaverse to increase awareness of prostate cancer. A total of 119 participants, including patients, caregivers, and members of the general population, completed the survey within the metaverse space and assessed their satisfaction and perceived awareness using a 5-point Likert scale. Results: The mean educational satisfaction score was 4.17 (SD 0.65), the mean psychological satisfaction score was 4.06 (SD 0.70), the mean overall satisfaction score was 4.12 (SD 0.72), and the mean awareness score was 4.09 (SD 0.72) out of a possible 5 points. Among responses rated 4 or higher (“agree” or “strongly agree”), 82.8% (394/476) were in the educational aspect, 76.6% (365/476) in psychological satisfaction, 81% (289/357) in overall satisfaction, and 80.4% (287/357) in awareness. Statistical analysis revealed significant differences in psychological (median 4.0, IQR 3.50-4.63, vs median 4.50, IQR 4.0-4.56) and overall (median 4.0, IQR 3.67-4.83, vs median 4.33, IQR 4.0-4.67) aspects between the general population group and patients and caregivers (median 4.0, IQR 3.33-4.33, vs median 4.67, IQR 4.0-4.67). Conclusions: The findings suggest that the metaverse holds promise as a platform for health care education and patient support, offering accessible and engaging experiences for patients, caregivers, and members of the general population. Our approach demonstrated a positive influence on participants’ satisfaction and perceived awareness, highlighting its potential to enhance health communication and patient engagement. Despite these encouraging results, limitations, such as the sample being skewed toward younger participants and reliance on self-reported data, underscore the need for more rigorous and multidimensional assessment strategies. Future studies should incorporate objective knowledge assessments, behavioral follow-ups, and qualitative methods to better evaluate the intervention’s effectiveness. This study provides early evidence that metaverse-based interventions can support disease awareness and promote preventive health behaviors, contributing to the ongoing evolution of digital health education.
- 13 May 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e63030
Open AccessAnalyzing Usage of the Metaverse by Associations of Patients With Prostate Cancer During the 2023 Blue Ribbon Campaign: Cross-Sectional Survey Study
Background: It is important to explain early diagnosis and treatment plans to patients of prostate cancer due to the different stages that diagnosis is made at and the corresponding stage-specific treatment options, as well as the varying prognoses depending on the choices made. Although various studies have implemented metaverse-based interventions across diverse clinical settings for medical education, there is a lack of publications addressing the implementation and validation of patient education using this technology. Objective: This study explored the potential of the metaverse as an educational and informational tool for prostate cancer. We measured and analyzed participants’ satisfaction and perceptions following a metaverse-based prostate cancer awareness campaign. We also evaluated the feasibility and potential effectiveness of the metaverse as a platform for hosting a virtual patient association and delivering health education. Methods: The study was conducted via a questionnaire administered from September 15 to October 20, 2023, during the Blue Ribbon Campaign organized by the Korean Urological Association and the Korean Society of Urological Oncology. The postevent questionnaire was designed to assess the effectiveness of using the metaverse to increase awareness of prostate cancer. A total of 119 participants, including patients, caregivers, and members of the general population, completed the survey within the metaverse space and assessed their satisfaction and perceived awareness using a 5-point Likert scale. Results: The mean educational satisfaction score was 4.17 (SD 0.65), the mean psychological satisfaction score was 4.06 (SD 0.70), the mean overall satisfaction score was 4.12 (SD 0.72), and the mean awareness score was 4.09 (SD 0.72) out of a possible 5 points. Among responses rated 4 or higher (“agree” or “strongly agree”), 82.8% (394/476) were in the educational aspect, 76.6% (365/476) in psychological satisfaction, 81% (289/357) in overall satisfaction, and 80.4% (287/357) in awareness. Statistical analysis revealed significant differences in psychological (median 4.0, IQR 3.50-4.63, vs median 4.50, IQR 4.0-4.56) and overall (median 4.0, IQR 3.67-4.83, vs median 4.33, IQR 4.0-4.67) aspects between the general population group and patients and caregivers (median 4.0, IQR 3.33-4.33, vs median 4.67, IQR 4.0-4.67). Conclusions: The findings suggest that the metaverse holds promise as a platform for health care education and patient support, offering accessible and engaging experiences for patients, caregivers, and members of the general population. Our approach demonstrated a positive influence on participants’ satisfaction and perceived awareness, highlighting its potential to enhance health communication and patient engagement. Despite these encouraging results, limitations, such as the sample being skewed toward younger participants and reliance on self-reported data, underscore the need for more rigorous and multidimensional assessment strategies. Future studies should incorporate objective knowledge assessments, behavioral follow-ups, and qualitative methods to better evaluate the intervention’s effectiveness. This study provides early evidence that metaverse-based interventions can support disease awareness and promote preventive health behaviors, contributing to the ongoing evolution of digital health education.
- Open Access
- 22 April 2025
- Published by MDPI AG in Preprints.org
Heterogeneous Responses to Combination Therapy of Anti-AR Antagonists and mTORi: Analysis of Gene Expression Profiles Across Prostate Cancer Cell Lines
Background: Combination therapies targeting different pathways, such as mTOR inhibitors and AR antagonists, have been explored for treating castration-independent prostate cancer. However, their success has been limited. Materials and Methods: Four prostate cancer cell lines with varying metastatic potential were analyzed for sensitivity to combination therapy using proliferation, western blot, and viability assays. Gene set expression profiles were compared to identify correlations with drug sensitivity. Gene set enrichment profiles of malignant versus benign cell lines were also analyzed using CCLE data. Results: The cell lines showed varying sensitivity to the combination therapy, which correlated with distinct gene expression and enrichment profiles. These patterns were linked to drug resistance and metastatic potential. Additionally, several genes were identified as promising therapeutic targets for prostate cancer. Conclusions: This study demonstrates significant heterogeneity in drug resistance and metastatic potential among prostate cancer cell lines. Unique gene expression patterns linked to these characteristics were identified, providing insights for developing targeted therapies and advancing prostate cancer treatment.
- 22 April 2025
- Published by MDPI AG in Preprints.org
Open AccessHeterogeneous Responses to Combination Therapy of Anti-AR Antagonists and mTORi: Analysis of Gene Expression Profiles Across Prostate Cancer Cell Lines
Background: Combination therapies targeting different pathways, such as mTOR inhibitors and AR antagonists, have been explored for treating castration-independent prostate cancer. However, their success has been limited. Materials and Methods: Four prostate cancer cell lines with varying metastatic potential were analyzed for sensitivity to combination therapy using proliferation, western blot, and viability assays. Gene set expression profiles were compared to identify correlations with drug sensitivity. Gene set enrichment profiles of malignant versus benign cell lines were also analyzed using CCLE data. Results: The cell lines showed varying sensitivity to the combination therapy, which correlated with distinct gene expression and enrichment profiles. These patterns were linked to drug resistance and metastatic potential. Additionally, several genes were identified as promising therapeutic targets for prostate cancer. Conclusions: This study demonstrates significant heterogeneity in drug resistance and metastatic potential among prostate cancer cell lines. Unique gene expression patterns linked to these characteristics were identified, providing insights for developing targeted therapies and advancing prostate cancer treatment.
- Open Access
- 10 April 2025
- Published by Elsevier in Materials Today Bio
- Vol. 32, 101754
Hollow microneedles as a flexible dosing control solution for transdermal drug delivery
- 10 April 2025
- Published by Elsevier in Materials Today Bio
- Vol. 32, 101754
Open AccessHollow microneedles as a flexible dosing control solution for transdermal drug delivery